Clearside Biomedical is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space, or SCS. Co.'s SCS injection platform, utilizing its proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Co.'s SCS injection platform can be used in conjunction with existing drugs designed for delivery to the SCS, therapies and future therapeutic inventions. The CLSD stock yearly return is shown above.
The yearly return on the CLSD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CLSD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|